

Italian Bio Products S.r.l.
Strada Ribocca 11
15057 Tortona (AL)
Italy
Att. the Chairman

The undersigned, acting as legal representatives of the Company, Novozymes A/S ("Novozymes" or "Company"), shareholder of Beta Renewables S.p.A. ("Beta"), owning a share of 9,95% of its corporate capital, hereby declare as follows:

22 February 2018

Novozymes A/S
Krogshøjvej 36
2880 Bagsværd
Denmark

Telephone: +45 4446 0000

CVR: 10007127
www.novozymes.com

- (i) The Company is aware of the fact that (a) Italian Bio Products S.r.l. ("IBP") – together with other companies members of the Mossi & Ghisolfi Group, including Beta – was admitted to the procedure for composition with creditors known as '*reserved*' (*concordato preventivo 'riservato'*), ex art. 161, sixth paragraph, of the Italian Bankruptcy Law, pursuant to an application filed on October 16, 2017. The procedure for composition with creditors is currently pending before the Court of Alessandria, docket number 13/2017 C.P., Delegated Judge dr. Enrica Bertolotto, Judicial Commissioners dr. Pietro Canevelli, Claudio Ferrario and dr. Silvano Cremonesi.
- (ii) The Company has acknowledged the fact that IBP – within the deadline of 22 February 2018 granted by the Court of Alessandria – shall proceed by formally filing the plan and proposal for composition with creditors, together with the documentation further required by art. 161, second and third paragraphs, of the Italian Bankruptcy Law, thus requesting its admission to the procedure for composition with creditors known as '*full*' (*concordato preventivo 'pieno'*).
- (iii) Based on the information provided by IBP legal counsels to the Company: (i) on 21 February 2018 Versalis (a company belonging to ENI's group) submitted a binding offer for 75 million Euro for the purchase of the so-called "*Perimetro Bio*", which includes assets belonging to both IBP and Beta (the "**Offer**"); (ii) IBP and Beta intend to use the Offer to build up their respective plans for composition with creditors that they are about to file with the appropriate court; (iii) more specifically, IBP's plan for composition with creditors (which IBP is finalizing), provides for, among other things, the sale to third parties of the business related to the so-called '*Perimetro Bio*', even if this the latter includes, as already mentioned and among other, some assets owned by Beta (the "**Beta Business Unit**").

- (iv) The Company has also been informed of the fact that, within sixty days from the expiration of the deadline for the filing of IBP's plan, also the other companies of the '*Perimetro Bio*', including Beta, will file their respective plans and proposal for the "full" compositions with creditors, which will provide for the sale of the respective business units, including the Beta Business Unit.

In light of the above, the undersigned, acting as legal representatives of Novozymes, declare that they do not have, at present, any reason that prevents them to vote in favour - in the soon-to-be-convened shareholders' meeting - of the authorisation to the sale of Beta's assets, including the Beta Business Unit, based on the provisions of the Offer, as communicated to us (or in any case at better conditions than those set forth in the Offer) and in the framework of the proposal for a "full" composition with creditors that Beta will file within the terms provided by law and before the appropriate Court, without prejudice or limitation to the Company's position once the proposal and the related plan for the composition with creditors have been duly examined.

Faithfully,



Peder Holk Nielsen
CEO



Thomas Videbæk
COO

